share_log

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144：拟议出售证券
SEC announcement ·  03/15 16:51
Moomoo AI 已提取核心信息
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 20,000 shares of common stock on 03/15/2024, with an aggregate market value of $1,449,628. The shares to be sold were acquired on the same date through a stock option exercise from the issuer, with payment made in cash. This transaction follows a series of sales over the past three months, where a total of 110,755 shares were sold for gross proceeds of $7,498,550.49.
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 20,000 shares of common stock on 03/15/2024, with an aggregate market value of $1,449,628. The shares to be sold were acquired on the same date through a stock option exercise from the issuer, with payment made in cash. This transaction follows a series of sales over the past three months, where a total of 110,755 shares were sold for gross proceeds of $7,498,550.49.
CRISPR Therapeutics AG高管兼董事萨玛斯·库尔卡尼定于2024年3月15日出售2万股普通股，总市值为1,449,628美元。拟出售的股票于同日通过发行人的股票期权行使收购，并以现金支付。该交易是在过去三个月进行了一系列销售之后进行的，共出售了110,755股股票，总收益为7,498,550.49美元。
CRISPR Therapeutics AG高管兼董事萨玛斯·库尔卡尼定于2024年3月15日出售2万股普通股，总市值为1,449,628美元。拟出售的股票于同日通过发行人的股票期权行使收购，并以现金支付。该交易是在过去三个月进行了一系列销售之后进行的，共出售了110,755股股票，总收益为7,498,550.49美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息